

PCPA UPDATE

July - September 2023

Q3 2023

A high-level summary of the quarterly pan-Canadian Pharmaceutical Alliance (pCPA) activity & processes

pCPA ACTIVITY



Initiated 15 files
(Q2 2023: 25 files)



Completed 14 files
(Q2 2023: 22 files)




Closed 5 files
(Q2 2023: 3 files)



Declined 1 file
(Q2 2023: 1 file)


FILES UNDER CONSIDERATION



Insights

- CADTH issued 10 positive and 4 'Do Not Reimburse' recommendations in Q3 2023. 8 recommendations were non-oncology and 6 were oncology.
- pCPA initiated negotiations for 15 files during the quarter. The volume of files under consideration was steady at 28 throughout Q3, below the volumes seen earlier in the year.
- The average days under consideration decreased from 195 days in Q2 to 175 days in Q3, bringing the average for the past year to 172 days.
- While most of the files initiated in Q3 were non-oncology (9 of 15), the volume under consideration in that category (20) is more than double the volume of oncology files under consideration (8).

FILES UNDER NEGOTIATION




Insights


- The volume of files under negotiation at pCPA was lower in Q3 compared to the rest of the year, as more files were completed (14), closed (5), or not negotiated (1) than were initiated (15).
- 2 of the files initiated in Q3 were drugs that had been previously negotiated at pCPA for the same indication. Neither had a new HTA recommendation, signaling that these are renegotiations.
- The volume of oncology files under negotiation was lower than non-oncology files throughout Q3.
- The average time under negotiation increased slightly from 97 days in Q2 to 103 days in Q3. The average days under negotiation for the past year is 109 days, having remained fairly consistent across the most recent three quarters.

pCPA CAPACITY

Volume of Processed Files



Long Term Files



Insights

- pCPA completed 14 negotiations (4 oncology, 6 non-oncology, and 4 "other") with LOIs in Q3 2023, closed 5 negotiations (3 oncology and 2 non-oncology) without LOIs, and declined to negotiate 1 oncology file which had a negative HTA recommendation.
- The total volume of files adjudicated in Q3 (20) was lower than that of previous three quarters, and was lower than Q3 of 2022 (23).
- 1 of the files that closed, Dayvigo, had a negative CADTH recommendation but a positive INESSS recommendation.
- The number of files under consideration for more than 6 months decreased over the quarter from 10 to 7. 4 of those 7 files have been under consideration for over 1 year. The number of files under negotiation for more than 12 months remained at 0 throughout the quarter.

